← All trials
NCT05658692
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2022
- Primary completion
- Oct 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Dec 21, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 1000
- Arms / groups
- 14 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Harbin Medical UniversityCollaborator
- Sichuan UniversityCollaborator
- Wuhan UniversityCollaborator
- Fudan UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Zhejiang UniversityStudy director
- Ningbo No. 1 HospitalCollaborator
- Shantou UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.